CVS Health Opens First Pharmacy-Only Location in Chicago
CVS Health unveiled the first of nearly 20 pharmacy-only, apothecary-style CVS Pharmacy locations it plans to open this year to increase access to pharmacy care. The new pharmacy, located at 2628 West Pershing Road in Chicago's West End, will help bridge gaps in care and make it easier for community members to access medications, immunizations and other health care services provided by pharmacists. Pharmacy-only locations will open in areas across the country, increasing access to vital pharmacy care, creating a simple and convenient way for community members to seek pharmacist support. Each site will feature a full-service pharmacy with a customized selection of over-the-counter products available for purchase. With footprints averaging around 3,000 square feet, the pharmacy-only sites will help ensure patients have access to prescription medications and the trusted advice and counsel of their neighborhood CVS pharmacist.
Trade with 70% Backtested Accuracy
Analyst Views on CVS
About CVS
About the author

- Asset Purchase Agreement: Omnicare has entered into an asset purchase agreement with GenieRx Holdings, which will act as the 'stalking horse bidder' in the company's court-supervised sale process, marking a significant step forward in the ongoing restructuring efforts.
- Bidding Deadline: Interested parties must submit competing bids by April 30, 2026, and if qualified bids are received, an auction is expected on May 5, 2026, potentially increasing the final sale price of Omnicare's assets through competitive offers.
- Ongoing Customer Support: Throughout the sale process, Omnicare remains focused on supporting its customers and ensuring residents receive safe and reliable pharmacy care, while addressing the complexities of long-term care through transparent pricing and clinical programs.
- Strategic Partnership Model: Omnicare emphasizes a partnership-driven approach to pharmacy services for assisted living communities, aimed at enhancing resident care quality and communication experiences, which will help the company maintain its competitive edge in an increasingly complex healthcare environment.
- Asset Purchase Agreement: Omnicare has entered into an asset purchase agreement with GenieRx Holdings LLC, with GenieRx serving as the 'stalking horse bidder', marking a significant step in Omnicare's court-supervised sale process and setting a floor for the eventual sale of the company's assets.
- Bidding Deadline: Interested bidders must submit their offers by April 30, 2026, and if qualified bids are received, an auction is expected on May 5, 2026, which will influence Omnicare's asset disposal strategy and future financial condition.
- Clinical Support Services: Omnicare continues to focus on assisting skilled nursing and assisted living providers in navigating the complexities of long-term care, enhancing its market competitiveness through transparent pricing and clinical programs aligned with CMS value-based purchasing measures.
- Customer Relationship Maintenance: Throughout the court-supervised sale process, Omnicare is committed to ensuring that customers and residents continue to receive safe and reliable pharmacy services, which not only helps maintain customer trust but also enhances the company's brand image in future market competition.
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
- Community Pharmacy Openings: CVS Health plans to open nearly 20 pharmacy-only locations in 2026, starting with one in Chicago, aimed at enhancing residents' access to medications and immunization services, thereby improving community health service accessibility.
- Customized Offerings: The new pharmacies will feature a tailored selection of over-the-counter products, with an average footprint of 3,000 square feet, ensuring patients can conveniently access prescription medications and professional pharmacist advice, which is expected to boost patient satisfaction and loyalty.
- Diverse Pharmacy Formats: By introducing pharmacy-only locations alongside traditional pharmacies, in-store pharmacies, and MinuteClinics, CVS aims to meet the varied health needs of different communities while optimizing its retail footprint to adapt to industry shifts.
- Importance of Face-to-Face Interactions: According to the 2025 CVS Health Rx Report, 80% of patients prefer in-person pharmacy care, and CVS is ensuring patients have multiple service options to choose from based on their individual needs, thereby enhancing overall service delivery.

- Pharmacy Locations: CVS Health is planning to open pharmacy-only locations in several communities in 2026, in addition to a new site in Chicago.
- Community Focus: The initiative aims to enhance access to pharmacy services in various neighborhoods, reflecting a commitment to community health.









